Inactivating RIPK1 kinase by introducing RIPK1-D138N mutation in hepatocellular TAK1-deficient mice significantly ameliorated liver pathology by preventing hepatocyte apoptosis and subsequently reduced HCC development53. Here, RIPK1 is linked to hepatocellular carcinoma.